th PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 46 Annual Health Care Conference on Monday, March 2, 2026. The company will take part in a fireside chat beginning at 9:50 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives T ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

Market Overview - The Dow Jones Industrial Average closed down 821.91 points (-1.66%) at 48,804.06, with Dow Futures falling 857.00 points (-1.73%) to 48,817.00, driven by a sudden 15% blanket tariff announcement that reignited trade war fears and global economic uncertainty [1] - The Federal Reserve's hawkish commentary suggested a "coin flip" for future rate cuts, leading to a significant rotation from cyclical and growth sectors into defensive assets [1] Sector Performance Financial Sector - Financial stocks were the primary laggards amid rising recessionary fears, with American Express (AXP) dropping 7.48% to $320.12, JPMorgan Chase & Co. (JPM) falling 4.19% to $297.74, and Goldman Sachs (GS) decreasing by 3.44% [2] Technology Sector - The tech sector faced pressure due to AI-related disruption fears, with Salesforce (CRM) tumbling 5.10%, IBM (IBM) shedding 4.17%, and Microsoft (MSFT) declining by 2.61% [2] Defensive Sectors - Investors sought safety in consumer staples and healthcare, with Walmart (WMT) leading gainers at 2.76% to $126.43, followed by Procter & Gamble (PG) at 2.50%, and McDonald's (MCD) gaining 1.84% [3] - Apple (AAPL) bucked the tech trend with a 1.81% increase to $269.28, while healthcare giants Amgen (AMGN) and Johnson & Johnson (JNJ) advanced 1.57% and 1.32%, respectively [3]

New York, New York--(Newsfile Corp. - February 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-Nationa ...

Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWS ...

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, alleging that the company concealed manufacturing deficiencies related to its CELLECTRA device, which is crucial for its DNA medicine platform, leading to significant delays in the Biologics License Application submission timeline [1][2][3]. Group 1: Allegations of Manufacturing Deficiencies - The lawsuit claims that Inovio represented its CELLECTRA devices as "validated and manufactured under Current Good Manufacturing Practices (cGMP)" while allegedly hiding manufacturing issues with the single-use disposable administration component [2][4]. - A specific manufacturing issue was identified during routine testing, which is said to have stemmed from a plastic molded part within the array component [4][7]. Group 2: Impact on Biologics License Application (BLA) - The complaint alleges that these manufacturing deficiencies caused a full-year delay in the BLA submission timeline, moving the projected submission from the second half of 2024 to mid-2025 [3][7]. - Retesting of the CELLECTRA device was required due to these issues, further extending the timelines for the BLA submission [7]. Group 3: Importance of Accurate Disclosure - The integrity of the CELLECTRA device is deemed critical to Inovio's commercial transition, making accurate disclosure of its manufacturing status essential for investors [4]. - The case raises significant questions regarding manufacturing disclosure obligations within the biotechnology sector, highlighting the importance of transparency for investor trust [5].

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost February 23, 20268:15 PM UTCUpdated ago By Ahmed Aboulenein U.S. Food and Drug Administration Commissioner Marty Makary speaks during a press conference at the Department of Health and Human Services in Washington, D.C., U.S., November 10, 2025.... Purchase Licensing Rights, opens new tab Read ...

"Boring" may be just what the doctor ordered in this volatile market.Over the past few years, the exciting field of artificial intelligence (AI) has captured much of Wall Street's attention and headlines. And sure enough, some of the leaders in AI have produced incredible returns and might continue doing so. However, investors shouldn't ignore businesses that may not be as exciting, but more than make up for that with other qualities that can slowly increase wealth over time.One such company is Abbott Labor ...

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’s top growth stock picks. On February 18, Eli Lilly and Company (NYSE:LLY) said using Taltz (ixekizumab) together with Zepbound (tirzepatide) worked better than Taltz alone in adults who had moderate-to-severe plaque psoriasis and also had obesity or were overweight. Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal Eli Lilly said the results came from its Phase 3b TOGETHER-PsO study, which tested Taltz alone vs. Talt ...